Program
ocankitug
Also written as “CM326”, “CM326(formulation 1)” and “CM326(formulation 2)”.
Its studies are mostly in Asthma · Nasal Polyps · Dermatitis, Atopic · Pulmonary Disease, Chronic Obstructive, led by 2 companies.
Drug pageOcankitug: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 81 open or running | phase 2since Dec 13, 2021 | Apr 8, 2021 | none ahead |
| CSPC Pharmaceutical Groupits history only | 54 open or running | phase 3since Jan 11, 2026 | Mar 6, 2023 | Jul 1, 2027phase 2 · NCT07418736 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
CM326
, phase 3, as of Aug 20, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseCSPC (JMT-Bio) licensed it from Keymed, for mainland China, in all uses since November 2024 (respiratory diseases before).Agreed Nov 2021 · Source: Keymed Biosciences (HKEX announcement), Mar 24, 2025
History and studies of Keymed Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 8, 2021First study: phase 1 study in AsthmaFirst studyNCT04842201 · 44 enrolled · China
- Nov 2021CSPC (JMT-Bio) licensed it from KeymedLicenseMainland China, in all uses since November 2024 (respiratory diseases before) · agreed · Keymed Biosciences (HKEX announcement)
- Dec 9, 2021Phase 1 study in AsthmaNCT05171348 · 40 enrolled · China
- Dec 13, 2021Phase 2 study in Moderate-to-severe Atopic DermatitisNCT05186922 · 54 enrolled · China
- Mar 18, 2022Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT05324137 · 88 enrolled · China
- Dec 26, 20222 phase 2 studiesNCT05671445, NCT05671432
- Jan 27, 2023Phase 1 study in HealthyNCT05715333 · 46 enrolled · China
- Feb 29, 2024Named ocankitugINNProposed as its International Nonproprietary Name in WHO's List 130 · before, CM326
- Apr 15, 2024Phase 2 study in Chronic Rhinosinusitis With Nasal PolypsNCT06372678 · 90 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 Keymed Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06372678Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Not yet recruiting | Jun 30, 2026 | 90 |
| NCT05715333Healthy · China | 1 | Completed | Oct 4, 2023 | 46 |
| NCT05671445Dermatitis, Atopic · China | 2 | UNKNOWN | Mar 28, 2024 | 100 |
| NCT05671432Moderate-to-severe Atopic Dermatitis · China | 2 | UNKNOWN | Dec 30, 2023 | 240 |
| NCT05324137Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Completed | Mar 29, 2024 | 88 |
| NCT05186922Moderate-to-severe Atopic Dermatitis · China | 2 | UNKNOWN | Jan 2023 | 54 |
| NCT05171348Asthma · China | 1 | Completed | Oct 11, 2022 | 40 |
| NCT04842201Asthma · China | 1 | Completed | Sep 28, 2021 | 44 |
How it is read
Names in the registry
- “CM326”, 10 entries
- “CM326(formulation 1)”, 1 entry
- “CM326(formulation 2)”, 1 entry
- “CM326 injection”, 1 entry
- “CM326 dose 1”, 1 entry
Conditions, from the studies’ own filings
- Asthma, 4 studies
- Nasal Polyps, 3 studies
- Dermatitis, Atopic, 3 studies
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.